-
26m 30sPart 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney
-
5m 48sPart 1 | Session 2 The PARAGLIDE-HF Trial
-
13m 32sPart 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi
-
4m 3s
-
2m 45sPart 2 | Session 1 MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring
-
6m 54s
-
3m 11sPart 2 | Session 3 APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis
-
4m 45sPart 2 | Session 4 DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction
-
8m 47sPart 2 | Session 5 DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF
-
4m 53sPart 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients
-
3m 56sPart 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF
-
5m 11sPart 2 | Session 8 TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure
-
8m 22sPart 2 | Session 9 Diagnosis in Heart Failure in Women
Dr Jawad Haider Butt (Copenhagen University Hospital, DK) outlines the findings of a patient-level meta-analysis of the DAPA-HF and DELIVER trials, which studied the safety and effectiveness of dapagliflozin on patients with both peripheral arterial disease and heart failure. These trials covered the spectrum of patients with heart failure.
The findings of this meta-analysis suggest that dapagliflozin is effective in reducing the composite of worsening heart failure and cardiovascular death. This beneficial effect is not modified by PAD status. The risk of amputation within this patient cohort was not increased with dapagliflozin treatment as compared to placebo.
Interview Questions:
- What is the importance of this trial?
- What was the patient cohort and study design?
- What is the data presented at HFA 23?
- How should these findings be put into clinical practice?
- What are the next steps?
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.
Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.
For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.
Comments